Supreme Showdown

Arguments will be heard Monday in the Myriad Genetics gene patenting case.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Actually whole genome

Actually whole genome sequencing would infringe patents if used for diagnostic purposes. This is the point - Myriad does not limit research on BRCA1 and BRCA2 but does stop any other lab from using tests on these gene for clinical purposes.

Because Dr. Warren is not a

Because Dr. Warren is not a patent attorney I would respectfully assert that he is not in a position to opine as to whether "whole genome sequencing would infringe patents."